Wedbush Reiterates Outperform on Climb Bio, Maintains $20 Price Target

Benzinga · 1d ago
Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $20 price target.